Pacific Biosciences of California (PACB) closed the most recent trading day at $1.65, moving -1.5% from the previous trading session.
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the international Consortium for Long-Read Sequencing (CoLoRS), today announced the launch of the first publicly available and free HiFi long-read variant frequency database with global representation. This innovative resource fills a critical void for rare disease researchers, providing access to genetic variants that are not detectable through short-read sequencing methods. B
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.